| Study type |
No. of patients |
Treatment |
Effect |
Author |
| Case report |
1 |
MTX |
almost complete remission |
Dogra et al. (2004) |
| Case report |
1 |
MTX |
remarkable clearance |
Dogra et al. (2005) |
| Case report |
1 |
MTX |
full skin recovery |
Teran et al. (2010) |
| Case report |
1 |
MTX |
responded well |
Björksten et al. (1975) |
| Case report |
1 |
MTX |
marked improvement |
Kalla et al. (1996) |
| Case report |
2 |
MTX |
significant improvement |
Garg et al. (2011) |
| Case report |
1 |
MTX |
switched from acitretin to mtx |
Popadic et al. (2014) |
| Retrospective Case series |
13 |
MTX |
11 achived clearance with small residual plaques |
Collin et al. (2008) |
| Retrospective Case series |
24 |
MTX |
22 patients reached PASI 75; 2 achived PASI 50-75 |
Kaur et al. (2008) |
| Retrospective Case series |
7 |
MTX |
7 achived>75% clearance |
Kumar et al. (1994) |
| Retrospective Case series |
4 |
MTX |
4 had good responses |
Juanqin et al. (1998) |
| Retrospective Case series |
25 |
MTX |
40% achived PASI 75 at week 36 |
Geel et al. (2015) |
| Case report |
1 |
Cyclosporine |
marked response |
Nakamura et al. (2009) |
| Case report |
1 |
Cyclosporine |
resolved completely |
Xiao et al. (2007) |
| Case report |
1 |
Cyclosporine |
1 successfully managed |
Kim et al. (2006) |
| Case report |
1 |
Cyclosporine |
free of psoriasis |
Alli et al. (1998) |
| Case report |
1 |
Cyclosporine |
PASI 40.7 to 4.8 |
Wollina et al. (2001) |
| Case series |
4 |
Cyclosporine |
2 achived remission |
Popadic et al. (2014) |
| Case series |
2 |
Cyclosporine |
Consistent clearing |
Campione et al. (2014) |
| Case series |
6 |
Cyclosporine |
3 achived complete remission, 3 responded on dose increase |
Pereira et al. (2006) |
| Case series |
4 |
Cyclosporine |
4 unsatisfactory results |
Mahé et al. (2001) |
| Case series |
3 |
Cyclosporine |
3 achived clearance |
Kilic et al. (2001) |
| Case series |
3 |
Cyclosporine |
3 effective |
Perrett et al. (2003) |
| Case series |
17 |
Retinoids |
good response |
Popadic et al. (2014) |
| Retrospective Case series |
10 |
Retinoids |
10 improved (7 completely) |
Rosinska et al. (1988) |
| Retrospective Case series |
11 |
Retinoids |
7 excellent response, 4 moderat-good response |
Juanqin et al. (1998) |
| Case report |
1 |
Retinoids |
improved |
Umezawa et al. (2012) |
| Case report |
1 |
Retinoids |
complete clearance |
Van der Kerkhof et al. (1985) |
| Case report |
1 |
Retinoids |
cleared |
Kopp et al. (2004) |
| Case report |
1 |
Retinoids |
complete remission |
Salleras et al. (1995) |
| Case report |
1 |
Retinoids |
partial remission |
Judge et al. (1993) |
| Case report |
1 |
Retinoids |
marked improvement |
Chao et al. (2009) |
| Case report |
1 |
Retinoids |
complete remission, then relapse and then improvement |
Ergin et al. (2008) |
| Case report |
1 |
Retinoids |
minimal disease activity |
Liao et al. (2002) |
| Case report |
1 |
Retinoids |
good results but relapse |
Mazzatenta et al. (2005) |
| Case series |
2 |
Retinoids |
marked improvement |
Shelnitz et al. (1987) |
| Case series |
2 |
Retinoids |
2 excellent response |
Van der Rhee et al. (1980) |
| Case series |
7 |
Retinoids |
3 disease free, 4 lost |
De Oliveira et al. (2010) |
| Case report |
1 |
Retinoids |
excellent outcome |
Al-Shobaili et al. (2007) |
| Retro-spectiveCase series |
14 |
FAE |
5 complete clearance, 1 good response, 3 partiel response, 5 non-response |
Balak et al. (2013) |
| Retro-spectiveCase series |
6 |
FAE |
6 achived PASI 75-100 |
Steinz et al. (2014) |
| Case report |
1 |
FAE |
succesfull treatment |
Gerdes et al. (2011) |
| Retro-spectiveCase series |
14 |
FAE |
9 achieved improvement in PASI |
Geel et al. (2015) |
| Randomised controlled trial |
211 |
Etanerceptplacebo |
eg. After 12weeks: PASI 75:57% compared to 11% in placebo group |
Paller et al. (2008) |
| extended open-label/double blinded |
138 |
Etanercept |
eg. After 12 weeks: 70-85% maintained or regainded PASI 75 |
Siegfried et al. (2010) |
| extented open-label |
140 |
Etanercept |
47% achieved clear/almost clear |
Paller et al. (2010) |
| retrospective Case series |
9 |
Etanercept |
3 cleared, 4 much improved, 2 equivocal |
Hawrot et al. (2006) |
| Case series |
4 |
Etanercept |
4 achived reduced PASI between 7-25.8 |
Papoutsaki et al. (2005) |
| Case series |
10 |
Etanercept |
10 clear/almost clear |
Kress et al. (2006) |
| Case report |
1 |
Etanercept |
PASI 37 to 1.2 after 12 weeks |
Fabrizi et al. (2007) |
| Case report |
1 |
Etanercept |
sustained improvement |
Safa et a.l (2007) |
| Case report |
1 |
Etanercept |
sustained improvement |
Floristan et al. (2011) |
| Case report |
1 |
Etanercept |
excellent response |
Fraga et al. (2011) |
| Case report |
1 |
Etanercept |
significant response |
Fialová et al. (2014) |
| Case report |
1 |
Etanercept |
no response, switched to infliximab |
Farnsworth et al. (2005) |
| Case report |
1 |
Etanercept |
slow improvement |
Pereira et al. (2006) |
| Case report |
1 |
Adalimumab |
near total resolution |
Callen et al. (2005) |
| Randomised controlled trial |
114 |
Adalimumab/MTX |
Adalimumab:57,9% achieved PASI 75; MTX: 32,4% achived PASI 75 |
ClinicalTrials (2015) |
| Case report |
1 |
Adalimumab |
complete resolution |
Alvarez et al. (2011) |
| Case report |
1 |
Infliximab |
marked clearing |
Farnsworth et al. (2005) |
| Case report |
1 |
Infliximab |
remission in 10months, then switched to etanercept |
Pereira et al. (2006) |
| Case report |
1 |
Infliximab |
improved |
Rott et al. (2007) |
| Case report |
1 |
Infliximab |
Complete remission |
Skrabl-Baumgartner et al. (2015) |
| Case report |
1 |
Infliximab |
significant improvement |
Menter et al. (2004) |
| Case report |
1 |
Ustekinumab |
1 year: PASI 100 |
Fotiadou et al. (2011) |
| Case report |
1 |
Ustekinumab |
8 weeks: PASI 100 |
Dixit et al. (2013) |
| Case report |
1 |
Ustekinumab |
8 weeks: PASI 100 |
AbuHilal et al. (2015) |
| Randomised controlled trial
|
110
|
Ustekinumab Placebo
|
12 weeks: |
Landells et al. (2015)
|
| >67% achived PGA 0/1 |
| >78% achived PASI 75 |
| >54% achived PASI 100 |
